PURPOSE: We tested the hypothesis that preoperative plasma levels of @entity22644 or @entity2301 would predict @entity5 stage and prognosis in @entity1 undergoing radical prostatectomy. MATERIAL AND METHODS: Plasma levels of @entity442 , @entity10513 , and @entity2301 were measured preoperatively in 120 consecutive @entity1 who underwent radical prostatectomy for clinically localized disease, postoperatively in 51 of these @entity1 , in 44 healthy @entity1 , in 19 @entity1 with @entity3 to regional lymph nodes, and in 10 @entity1 with bone @entity3 . RESULTS: Plasma @entity2301 levels were lowest in @entity1 with bone @entity3 (P < or = .043). @entity10513 levels were elevated in @entity263 @entity1 compared with healthy subjects (P < or = .006). However, within the group of prostatectomy @entity1 , preoperative plasma @entity10513 levels were lower in @entity1 with @entity1442 (P < or = .033), were inversely correlated with @entity263 volume (P =.037), and declined after prostate removal (P =.044). Lower preoperative @entity10513 and @entity2301 levels and biopsy Gleason score were independent predictors of biochemical progression (P =.043, P =.040, and P =.020, respectively). In @entity1 with disease progression, preoperative plasma @entity2301 levels were lower in those with @entity146 than in those with nonaggressive failure (P =.042). CONCLUSION: Elevation of plasma @entity10513 levels in @entity263 @entity1 apparently is due to increased release directly from the prostate. For @entity1 with clinically localized @entity263 , preoperative plasma @entity10513 levels are inversely associated with @entity146 . Preoperative plasma @entity2301 levels were decreased in @entity1 with @entity263 @entity3 and were an independent predictor of biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.

Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with @entity263 invasion, progression, and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic tumor', 'prostate cancer'] @entity2301 :: ('3486', 'Gene') :: ['IGFBP-3'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity146 :: ('MESH:D001523', 'Disease') :: ['biologically aggressive disease and disease progression', 'aggressive'] @entity442 :: ('3479', 'Gene') :: ['IGF-I'] @entity10513 :: ('3485', 'Gene') :: ['IGFBP-2'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity22644 :: ('474257', 'Gene') :: ['insulin-like growth factor (IGF) binding protein (BP)-2']
@entity3 :: (MESH:D009362,Disease) :: ['metastasis']
